Floatz logo

yl201

Small Cell Lung Cancer

MediLink Therapeutics (Suzhou) Co., Ltd.Phase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
65/ 100

Competitive context

290 Active assets in the Small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Benmelstobart
Yayi He
Phase 4A
vx-970
National Cancer Institute (NCI)
Phase 2BBB
Adebelimab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3BBB
Veliparib
Central European Society for Anticancer Drug Research
Phase 2BB
Hycamtin
AbbVie
Phase 4BB

View all 50 →

Same molecule, other indications

yl201 is also rated in:

Metastatic Castration-resistant Prostate Cancer (mCRPC)Dormant
CCC
Indicative ·
51 / 100
View asset →
cancerDormant
CC
Indicative ·
45 / 100
View asset →
Advanced Solid TumorDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →